NICE backs NHS use of Novartis’ cholesterol drug Leqvio
pharmaphorum
SEPTEMBER 1, 2021
As well as the access agreement for high-risk patients, the Novartis deal also covers a large-scale trial of the PCSK9 inhibitor and the creation of a consortium with academic groups aimed at improving the manufacturing of oligonucleotide drugs in the UK. This needs further thought,” he added.
Let's personalize your content